U.S., Dec. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07259213) titled 'A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC' on Nov. 15.
Brief Summary: A Phase 1/2a Study to Evaluate the Safety, Tolerability, Whole-Body Distribution, and Preliminary Clinical Activity of 161Tb-RAD402, a Radiolabeled Anti-KLK3 Monoclonal Antibody Targeting Free Prostate-Specific Antigen, in Participants with Castration-Resistant Prostate Cancer (CRPC).
Study Start Date: Nov. 30
Study Type: INTERVENTIONAL
Condition:
Castration-resistant Prostate Cancer
Intervention:
DRUG: 161Tb RAD402
161Tb RAD402 administered at treatment doses
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Radiopharm Theranostics, Lt...